Search research articles
Contact Us
Filters
Showing results (1-10 of 268) with videos related to
Page
of 27
Sort By:
The Oncologist
|
February 1, 2011
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
José Baselga
The Oncologist
|
August 31, 2002
Why the epidermal growth factor receptor? The rationale for cancer therapy
José Baselga
JAMA Oncology
|
November 14, 2018
Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology
José Baselga
JAMA
|
November 14, 2018
Failure to Disclose Conflict of Interest in Article Published in JAMA on Detection of Cancer-Related Genes
José Baselga
Clinical Advances in Hematology & Oncology : H&O
|
October 15, 2005
A review of EGFR targeted therapy
José Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2008
Creating a stronger front against cancer: ESMO and ECCO join forces
, José Baselga
JAMA Otolaryngology-- Head & Neck Surgery
|
November 14, 2018
Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology-Head & Neck Surgery
José Baselga
Nature Clinical Practice. Oncology
|
November 3, 2005
Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?
Josep Tabernero, José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
Emiliano Calvo, José Baselga
Page
of 27
Search research articles
Search
Showing results (1-10 of 268) with videos related to
Sort By:
Page
of 27
The Oncologist
|
February 1, 2011
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer
José Baselga
The Oncologist
|
August 31, 2002
Why the epidermal growth factor receptor? The rationale for cancer therapy
José Baselga
JAMA Oncology
|
November 14, 2018
Failure to Accurately Disclose Conflicts of Interest in Articles Published in JAMA Oncology
José Baselga
JAMA
|
November 14, 2018
Failure to Disclose Conflict of Interest in Article Published in JAMA on Detection of Cancer-Related Genes
José Baselga
Clinical Advances in Hematology & Oncology : H&O
|
October 15, 2005
A review of EGFR targeted therapy
José Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2008
Creating a stronger front against cancer: ESMO and ECCO join forces
, José Baselga
JAMA Otolaryngology-- Head & Neck Surgery
|
November 14, 2018
Failure to Accurately Disclose Conflicts of Interest in Article Published in JAMA Otolaryngology-Head & Neck Surgery
José Baselga
Nature Clinical Practice. Oncology
|
November 3, 2005
Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?
José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 4, 2010
Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?
Josep Tabernero, José Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2006
Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors
Emiliano Calvo, José Baselga
Page
of 27